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Abstract 
Background: Access to antiretroviral treatment (ART) in resource‑limited countries has increased significantly but 
scaling‑up ART into semi‑rural and rural areas is more recent. Information on treatment outcome in such areas is still 
very limited notably due to additional difficulties to manage ART in these areas.
Results: 387 HIV‑1 infected adults (≥18 years) were consecutively enrolled when attending healthcare services for 
their routine medical visit at 12 or 24 months on first‑line ART in five HIV care centers (four semi‑rural and one rural). 
Among them, 102 patients were on first‑line ART for 12 ± 2 months (M12) and 285 for 24 ± 2 months (M24). Virologi‑
cal failure was observed in 70 (18.1 %) patients ranging from 13.9 to 31.6 % at M12 and from 8.1 to 22.4 % at M24 
across the different sites. For 67/70 patients, sequencing was successful and drug resistance mutations were observed 
in 65 (97 %). The global prevalence of drug resistance in the study population was thus at least 16.8 % (65/387). More‑
over, 32 (8.3 %) and 27 (6.9 %) patients were either on a completely ineffective ART regime or with only a single drug 
active. Several patients accumulated high numbers of mutations and developed also cross‑resistance to abacavir, 
didanosine or the new NNRTI drugs like etravirine and rilpivirine.
Conclusion: The observations on ART treatment outcome from ART clinics in semi‑rural areas are close to previous 
observations in Lomé, the capital city suggesting that national ART‑programme management plays a role in treat‑
ment outcome.
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Findings
Background
Scale-up of antiretroviral treatment (ART) programs in 
resource-limited countries was possible because stand-
ardized first and second line antiretroviral (ARV) com-
binations and clinical and/or immunological criteria to 
start and monitor ART were used as recommended by 
WHO [1]. However, heterogeneous treatment outcomes 
have been observed in the national ART programs from 
different countries, most likely related to ART-pro-
gramme management [2]. As such, virological failure can 
range from less than 3 % to more than 20 % in patients on 
ART for 12 or 24 months [2–4].
In Togo, a country of six million inhabitants in West 
Africa, scaling-up of ART started in 2007 in Lomé, the 
capital city, and has expanded to semi-rural areas in 
2008. In 2013, almost 50 % of patients who were in need 
for ART according to WHO guidelines from 2010 (CD4 
count  <350) were receiving ART [5]. Previous studies 
in ART clinics in Lomé showed high virological failure 
related to ARV drug resistance, i.e. in 13 to 25 % of the 
patients receiving ART for 12 or 24 months [2, 6]. Given 
the additional difficulties to manage ART in these areas 
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(distances to clinics, scarce human resources, drug stock-
outs, etc.) together with high rates of ARV drug resist-
ance in the capital city, it was important to evaluate also 
virological outcome and emergence of drug resistance 




A cross-sectional study was conducted in 2012 between 
January and July in five HIV care centers that admin-
ister ARV drugs and monitor treatment. They were 
located in four semi-rural cities: Aného (AN), Kpalimé 
(KP), Atakpamé (AT) and Kara (KA) at respectively 60, 
120, 160 and 410 km from Lomé, the capital city, and in 
one rural city, Kouvé (KO) at 70 km distance from Lomé 
(Fig.  1). HIV-1 infected adults (≥18  years) were con-
secutively enrolled when attending clinics for their rou-
tine medical visit at 12 ± 2 months or 24 ± 2 months 
on first-line ART. This study was approved by the 
National Ethics Committee (nº751/2014/MS/CAB/
DGS/DPLET/CBRS). Informed consent was obtained 
for each participating patient. Questionnaires were 
used to collect epidemiological and demographic infor-
mation and ART history was obtained from on-site 
medical records. Whole blood was drawn and plasma 
was separated by centrifugation. Plasma aliquots were 
stored at −20 °C for maximum 1 week on site and were 
subsequently transported by road in a cool box to the 
Laboratoire de Biologie Moléculaire et d’Immunologie 
(BIOLIM/FSS-UL) where they were stored at −80  °C 
until use.
Virological analyses
HIV-1 viral load (VL) was determined with EasyQ HIV 
assay (Biomerieux, Capronne, France) or RealTime 
m2000rt (Abbott Pack, IL, USA) in Lomé (BIOLIM/FSS-
UL). According to WHO recommendations, genotypic 
drug resistance testing was done in a WHO accredited 
laboratory (IRD, Montpellier, France) on patients with 
VL ≥1000 copies/ml. Protease and partial Reverse Tran-
scriptase (RT) were amplified with the in-house protocol 
from the Agence Nationale de Recherche sur le Sida et 
les Hépatites en France (ANRS) [2, 7]. Drug resistance 
mutations (DRM) were identified using the ANRS inter-
pretation algorithm, version 24 [7]. The newly reported 
sequences are available in GenBank under the following 
accession numbers: KR047793–KR047859.
Results
A total of 387 patients were consecutively enrolled dur-
ing their follow-up visit at 12  ±  2 (M12, n  =  102) or 
24 ± 2 (M24, n = 285) months on ART. Table 1 shows 
patients characteristics at each site. Overall, more 
women were enrolled than men: 84/102 (82.4 %) at M12 
and 205/285 (71.9 %) at M24. The median age of patients 
was 36 (IQR 31–42) and 39  years (IQR 33–45) at M12 
and M24, respectively. More than 97  % (277/285) of 
patients have been exposed to the following drugs in 
their first line regimen: stavudine (d4T) and/or zido-
vudine (AZT) plus lamivudine (3TC) plus nevirapine 
(NVP) and/or efavirenz (EFV). For 302 (78 %) patients, 
d4T was replaced by AZT because national guidelines 
were changed. Only eight (2.8  %) patients switched to 
tenofovir (TDF) instead of AZT or d4T. At ART initia-
tion the overall median CD4 count/mm3 was 176 (IQR 
86–261) and 152 (IQR 88–219) for the patients who 
were on ART for 12  ±  2 and 24  ±  2  months, respec-
tively. Overall, 153/373 (41.1 %) and 220/373 (58.9 %) of 
the patients were in WHO stages 1 or 2 and WHO stages 
3 or 4, respectively at ART start. However, CD4 counts 
and WHO stages at ART initiation could vary across the 
different sites (Table 1).
Seventy patients (18.1  %; CI95 14.5–22.2  %) had 
VL >1000 copies/ml; 20/102 (19.6 %; CI95 13.4–29.2 %) 
at M12 and 50/285 (17.5 %; CI95 13.5–22.4 %) at M24. 
Virological failure ranged from 13.9 to 31.6  % at M12 
and from 8.1 to 22.4 % at M24. For 67 (95.7 %) patients, 
sequencing was successful and DRM were observed 
in 65 (97  %) of them; i.e. 20/20 at M12 and 45/47 at 
M24. Among the 65 drug resistant HIV strains, 59 
were resistant to NRTIs and NNRTIs, two to NRTIs 
only and four to NNRTIs only. The global prevalence 
of drug resistance in the study population was thus at 
least 16.8  % (13.4–20.9  %, 95  % CI) (65/387), but 27 
patients (6.9 %; 4.8–9.9 %, 95 % CI) were infected with 
HIV strains resistant to two of the three first-line ARVs 
and 32 (8.3 %; 5.9–11.4 %, 95 % CI) to all three first line 
ARVs.
As expected, the observed DRM were associated with 
the drugs used in first-line regimens (Table 2). M184 V 
selected by 3TC was the most frequent NRTI mutation, 
56/65 (86.2  %). Frequently observed TAMs included 
M41L, D67  N/D, K70R, K219E/Q and T215Y/F. The 
K65R mutation was seen in two patients. One-third 
of the patients had at least 3 or more NRTI mutations 
and several patients were already predicted to be resist-
ant to ABC (n =  12), DDI (n =  2) or tenofovir (TDF) 
(n  =  3). Among NNRTI mutations, Y181C/Y and 
K103N were most frequently observed and 15 (23.1 %) 
patients accumulated at least three NNRTI mutations, 
with 14 (21.5  %) and 44 (67.7  %) that were predicted 
to be resistant to second line NNRTIs ETV and RPV, 
respectively.
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Discussion
Overall, we showed that 18 % of patients on ART for 12 
or 24  months in semi-rural and rural ART clinics were 
on virological failure and almost all of them (97 %) were 
infected with drug resistant HIV-1 strains. These obser-
vations are high and close to what has been noticed in 
previous studies from Lomé, the capital city; for example 
in a survey conducted about 1 year earlier in 2010/2011 
using the same cross-sectional approach, 19 % (124/642) 
of patients for 12 or 24  months on ART were infected 
with HIV drug resistant strains [2]. Our study confirms 
thus a high ART failure in Togo in general and which is 
higher than observed in other countries, when compar-
ing with studies that used a similar approach [2]. Scale-
up of ART started in 2007 in the capital city and was 
expanded to semi-rural areas in 2008. Between 2006 and 
2012, the number of patients on ART increased from 
6700 to 31,500 but tools to monitor patients did not fol-
low this scale-up and training of medical personnel was 
insufficient to allow early detection of side_effects of 
certain ARVs, evaluate adherence or recognize rapi-
dely decline of clinical status. In addition, the national 
Fig. 1 Togo map indicating locations of the healthcare centers where patients were enrolled. The sites where samples were collected for this study 
are indicated with grey full circles, and the name of the corresponding city at the right. Lomé, the capital city, is indicated with a black full circle
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Table 2 Drug resistance mutations to the first line antiretroviral drugs after 12 and 24 months on ART
Patient code Months on ART NNRTI mutations NRTI mutations Subtype/CRF Accession
AN021 12 Y181V M41LM, M184V, T215F A3 KR047796
AN026 12 A98S, Y181C, G190A M41L, A62V, M184V, K219N CRF02_AG KR047798
AN052 12 K103KN M184V CRF06_cpx KR047805
AN058 12 V106A A62AV, M184V CRF02_AG KR047807
AN059 12 K103N M41L, M184V, T215Y CRF02_AG KR047808
AN074 12 K101E, G190A M184V CRF06_cpx KR047810
AT407 12 K101E, G190A M41L, D67N, K70R, V75IM, T215F, K219Q URF KR047840
AT411 12 Y181C, G190A M184V URF KR047841
AT423 12 K103N M184V CRF06_cpx KR047843
AT426 12 V90I, K101EQ, Y181C, G190S K65R CRF02_AG KR047844
AT477 12 K103N M184I G KR047850
KA305 12 Y181C M41L, M184V CRF06_cpx KR047851
KA308 12 K103N, Y181C, H221Y M184V, T215Y CRF06_cpx KR047852
KA348 12 Y181C M184V CRF06_cpx KR047855
KA350 12 K101E, G190A M41L, M184V URF KR047856
KA378 12 Y181C M41L, M184V, L210W, T215Y URF KR047858
KA379 12 K103N, Y181C M184I CRF02_AG KR047859
KP206 12 A98S, K103N, P225H M184V C KR047826
KP218 12 K101EK, G190A M184V CRF06_cpx KR047829
KP280 12 K103N M184V CRF02_AG KR047837
AN008 24 V179I, Y181CY, G190AG – URF KR047793
AN012 24 K103N – CRF02_AG KR047794
AN019 24 Y181C, H221Y M41L, V75I, M184V, T215F CRF02_AG KR047795
AN022 24 Y181C M184V URF KR047797
AN028 24 A98S, Y181C D67N, K70R, T215F, K219E CRF02_AG KR047799
AN032 24 Y181CY, G190AG, H221HY – URF KR047800
AN041 24 K103N, Y181C A62V, K65R, K70T, V75I, F116Y, Q151M, M184V CRF02_AG KR047801
AN043 24 K101E, Y181C, G190A M184V, T215F CRF02_AG KR047802
AN048 24 Y181C D67N, K70R, T215F, K219E CRF02_AG KR047803
AN049 24 K103N M184V CRF06_cpx KR047804
AN054 24 K103N M41L, E44D, L74I, M184V, L210W, T215Y CRF02_AG KR047806
AN068 24 Y181C, H221Y M41LM, M184V, T215Y CRF02_AG KR047809
AT400 24 Y181C K70KR, M184V CRF02_AG KR047838
AT403 24 – M184V A3 KR047839
AT420 24 K103N M184V CRF02_AG KR047842
AT435 24 Y181C, H221Y M41LM, D67DN, K70KR, T215Y, K219EK CRF02_AG KR047845
AT442 24 Y181C M184V, T215FIST CRF02_AG KR047846
AT452 24 Y181C M41L, M184V, T215Y CRF02_AG KR047847
AT456 24 K101E, G190A M184V, T215F CRF02_AG KR047848
AT463 24 – – CRF02_AG KR047849
KA319 24 A98S, K103N, Y181C D67N, K70R, M184V, T215F, K219Q URF KR047853
KA344 24 K101E, G190A M41L, D67DN, K70KR, M184V, T215Y G KR047854
KA366 24 K101E, Y181C, G190A M41L, M184V, L210W, T215Y URF KR047857
KO100 24 Y181C M41L, M184V, T215F CRF06_cpx KR047811
KO112 24 K103N, P225H K70DEKN, M184V CRF02_AG KR047812
KO116 24 K103N M184V URF KR047813
KO122 24 Y181C, H221Y M41L, D67N, K70R, M184V, T215Y G KR047814
KO130 24 K103N, E138 K M184V, T215F CRF02_AG KR047815
KO137 24 V179I, G190A, M230L M184V, T215Y A3 KR047816
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program encountered problems with stock management 
resulting in ARV drug substitution with the same mol-
ecules, administered separately as individual pills instead 
as a fixed dosed combination, or even interruption of the 
treatment. It is known that non-adherence and treatment 
interruption may favor emergence of drug resistance.
Today, only very few studies reported observations on 
ART outcome from semi-rural or rural areas in resource 
limited settings, especially from Africa [2, 8, 9]. In Cam-
eroon, 10 % of patients were infected with drug resistant 
HIV strains after a median of 12 months on ART in rural 
district hospitals at 50 to 150 km distance from Yaoundé, 
the capital city [10], which is close to rates observed in 
Yaoundé [2]. However, in a rural health center in Kolo-
fata, at the extreme north of Cameroon at 1200 km from 
the capital city and with difficult connections, almost 
30  % of patients on ART (median of 24  months) were 
resistant to ARV drugs [11]. Another report showed 
equal proportions of drug resistance in urban and rural 
areas, between 9.2 to 15.9 % after a median of 36 months 
on ART in Senegal, Mali and Guinea [12]. In rural and 
semi-rural settings in Gabon, 21  % of patients were 
resistant after a median of 33 months on ART [13]. In a 
rural clinic in Tanzania, rates of drug resistance were low 
and ranged from 4 to 8 % of patients after 1 or 2 years on 
ART, respectively [14]. Although, it is important to note 
that comparing results among the different studies men-
tioned above has to be taken with caution, because study 
design can differ as well as viral load capacities and tech-
niques to identify virological failure.
Overall it seems that treatment outcome varies among 
countries, but within countries treatment outcome in 
semi-rural settings seem to be similar to those in urban 
settings except in extreme conditions. These observa-
tions are in line with the fact that national ART-pro-
gramme management plays a role in treatment outcome 
in resource-limited countries [2]. It is important to note 
that we provided only information on the proportion of 
drug resistance in HIV infected patients who are still on 
ART and have no information on follow-up or mortal-
ity rates. Prospective studies where loss of follow-up are 
considered as treatment failures, would probable yield 
higher virological failure rates. Previous studies showed 
a higher mortality rate and loss of follow up in rural areas 
during the first 3 years [15].
Like in other reports on treatment outcome, several 
patients in our survey accumulated high numbers of 
mutations and developed also cross-resistance to poten-
tial second and/or third line drugs [16–18]. In addition 
these multi-drug resistant strains can also be transmitted 
and have a negative impact on future efficiency of first 
line regimens.
Conclusions
The observations on ART treatment outcome in semi-
rural areas show high failure rate but are close to those 
in Lomé, the capital city. Lowering the rates of drug 
resistance represents a challenge for the country. The 
first goals will be to identify factors associated with drug 
resistance.
Table 2 continued
Patient code Months on ART NNRTI mutations NRTI mutations Subtype/CRF Accession
KO148 24 K103N M184V CRF02_AG KR047817
KO150 24 K103N, Y181C M184V CRF02_AG KR047818
KO158 24 A98AG, K101E, Y181C D67N, K70R, M184V, T215F, K219E URF KR047819
KO193 24 K103N M184V CRF02_AG KR047820
KO195 24 Y181CY – CRF02_AG KR047821
KO197 24 V90I, V179I, G190A M184V A3 KR047822
KO200 24 E138EG – URF KR047823
KO203 24 Y181C, H221Y M184V, T215Y, CRF06_cpx KR047824
KP202 24 Y181C, H221Y M184V, T215Y CRF02_AG KR047825
KP210 24 G190S M184V CRF02_AG KR047827
KP213 24 K103N M184V, T215ST CRF02_AG KR047828
KP221 24 A98AS, K103N, E138Q, M41L, V75I, M184 V, T215F URF KR047830
KP223 24 K103N, Y181C,H221Y M41L, D67N, K70R, V75I, M184V, T215F, K219E, CRF02_AG KR047831
KP234 24 K103N M41L, M184V CRF06_cpx KR047832
KP235 24 V90IV, A98AG, E138Q, V179T M184V CRF02_AG KR047833
KP241 24 Y181V, H221Y M41L, M184V, L210W, T215F CRF02_AG KR047834
KP243 24 K101E, G190A M41L, D67N, M184V, L210W, T215Y URF KR047835
KP253 24 K103N M184V CRF02_AG KR047836
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